Fig. 5: GRP78-CAR T cells have potent anti-AML activity in vivo. | Nature Communications

Fig. 5: GRP78-CAR T cells have potent anti-AML activity in vivo.

From: CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells

Fig. 5

a Schematic of in vivo experimental design. b. MOLM13 xenograft model. NSG mice were injected with MOLM13 (5x103) cells i.v. (tail vein), and on day 7 received a single i.v. dose of 3 × 106 T cells. IVIS imaging was performed twice weekly. c Bioluminescence data (total flux = photons/s) d Survival curve (N = 5, p < 0.005, Log-rank test). Source data are provided as a Source data file.

Back to article page